Literature DB >> 5448745

Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy.

J Koch-Weser, V W Sidel, E B Federman, P Kanarek, D C Finer, A E Eaton.   

Abstract

Mesh：

Substances：

Year:  1970        PMID： 5448745     DOI： 10.7326/0003-4819-72-6-857

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  119 in total

1.  Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Timothy C Smeaton; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.

Authors:  Roberto Imberti; Maria Cusato; Giovanni Accetta; Valeria Marinò; Francesco Procaccio; Alfredo Del Gaudio; Giorgio A Iotti; Mario Regazzi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

3.  Colistin-Induced Apoptosis of Neuroblastoma-2a Cells Involves the Generation of Reactive Oxygen Species, Mitochondrial Dysfunction, and Autophagy.

Authors:  Chongshan Dai; Shusheng Tang; Tony Velkov; Xilong Xiao
Journal:  Mol Neurobiol       Date:  2015-08-28       Impact factor: 5.590

4.  Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.

Authors:  Cristina Miglis; Nathaniel J Rhodes; Sean N Avedissian; Christine J Kubin; Michael T Yin; Brian C Nelson; Manjunath P Pai; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 5.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.

Authors:  Matthew E Falagas; Sofia K Kasiakou; Sotirios Tsiodras; Argyris Michalopoulos
Journal:  Clin Med Res       Date:  2006-06

6.  Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide.

Authors:  R L Danner; K A Joiner; M Rubin; W H Patterson; N Johnson; K M Ayers; J E Parrillo
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.

Authors:  Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li
Journal:  ACS Infect Dis       Date:  2015-09-04       Impact factor: 5.084

10.  Efficacy and Safety of Intravenous Colistin in Very Low Birth Weight Preterm Infants.

Authors:  Ozkan Ilhan; Meltem Bor; Senem Alkan Ozdemir; Sinem Akbay; Esra Arun Ozer
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.